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Over the last decade, the care of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT)
has signiﬁcantly improved, leading to a decrease in deaths related to allo-HCT as well as improved long-term
survival. However, for many patients, long-term survivorship is associated with a substantial burden of
chronic morbidities. Indeed, malignant and nonmalignant late complications after allo-HCT are numerous and
usually multifactorial, with all organs and tissues a potential target. In many cases, these long-term side
effects are associated with the use of high-dose total body irradiation, myeloablative conditioning regimens,
and the onset of chronic graft-versus-host disease. It appears to be essential to change the natural history of
these late effects. This requires the introduction of improved conditioning regimens and the development of
lifelong monitoring controls, patient counseling, and preventative treatment measures. This approach will
allow us to pursue our efforts to improve patient outcome.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION measures to deal with the consequences of the therapeutic
Allogeneic hematopoietic cell transplantation (allo-HCT)
is an effective treatment for a range of malignant and
nonmalignant diseases. The main drawbacks of allo-HCT are
early transplant-related mortality and late complications,
with the latter impacting both quality of life and patient
outcomes. Over the last decade, advances have been made in
the care of patients undergoing transplantation, which has
led to a substantial reduction in deaths related to allo-HCT
and improved long-term survival [1]. Today, the aim of
allo-HCT is cure from the primary disease, and, independent
of cure, long-term survival with good quality of life is now an
expected outcome. However, the high intensity of therapy
and prolonged immune suppression increase the risk of
long-term complications and health care resource utilization
among survivors [2]. Also, the burden of long-termmorbidity
remains largely under-recognized, indicating an opportunity
to further improve patient outcomes through developingedgments on page 623.
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INCREASED SURVIVAL TREND IN ALLO-HCT
Studies suggest that changes in transplant practices have
led to improved mortality rates after allo-HCT. At a single
transplant center in Seattle, Gooley et al. [1] evaluated
various outcome measures among patients who received
their ﬁrst allo-HCT during the 2 periods: 1993 to 1997 and
2003 to 2007. Compared with the ﬁrst period, the second
period was associated with a 60% reduction in risk of day 200
nonrelapse mortality, a 52% reduction in overall nonrelapse
mortality, a 21% reduction in relapse or progression of ma-
lignancy, and a 41% reduction in overall mortality. Similar
results were seenwhen the analyses were limited to patients
receiving myeloablative conditioning. Improved outcomes
were related to reductions in risk of organ damage, infection,
and severe acute graft-versus-host-disease (GVHD). A recent
study conducted at a center in Nantes [3] comparing out-
comes among 827 allo-HCT patients who received their ﬁrst
transplant between 1983 and 2010 reported that patients in
the 2001 to 2010 cohort were signiﬁcantly older and pre-
sented with higher risk diseases compared with patients in
earlier cohorts (Figure 1). Despite this, nonrelapse mortality
was signiﬁcantly decreased and overall survival increased in
Figure 1. Improved outcome after allo-SCT in the last decade. (A) Overall survival. (B) Cumulative incidence of nonrelapse mortality. (Adapted from Malard et al. [3].)
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1991 to 2000 decades.
INCREASED SURVIVAL COMES AT A COST
Compared with the general population, mortality rates
among long-term survivors of allo-HCT remain high. In a
follow-up of 1479 individuals who survived 2 or more years
after allo-HCT, the conditional survival probability at 15 years
post-transplant was 80.2% [4]. However, compared with the
general population mortality remained signiﬁcantly
elevated, with a 2-fold higher mortality rate among 15-year
survivors of allo-HCT. Moreover, compared with their sib-
lings, allo-HCT survivors were more likely to report difﬁculty
in holding a job (odds ratio, 13.9) and in obtaining health
(odds ratio, 7.1) or life (odds ratio, 9.9) insurance [4]. This
under-recognized burden was further elaborated in a Bone
Marrow Transplant Survivor Study of 1022 HCT survivors and
309 siblings, which found that 66% of HCT survivors reported
at least 1 signiﬁcant chronic morbidity compared with 39%
of siblings, including 18% who reported severe or life-
threatening conditions compared with just 8% of siblings
[5]. HCT survivors with chronic GVHD were 4.7 times more
likely than the sibling group to develop severe or life-
threatening conditions, and the cumulative incidence of
chronic health conditions was highest after allo-HCT. Such
morbidity predicts ongoing health care resource utilization,
and this was conﬁrmed in a further report of the Bone
Marrow Transplant Survivor Study, which found in allo-HCT
survivors a reduction over time in prevalence of cancer/HCT-
related visits but no change in overall medical contacts and
an increase in general physical examinations [2]. Based on
these ﬁndings, it is possible to conclude that immediate
survival is no longer the major concern after allo-HCT. In
addition to achieving cure, the aims of treatment need to
include complete recovery of health status, normal physical
and psychological functioning, normal family and social
integration, and good subjective well-being [6].
COMPLICATIONS ASSOCIATED WITH ALLO-HCT
Malignant and nonmalignant late complications after
allo-HCT are numerous and usually multifactorial, with all
organs and tissues a potential target [7,8]. These can lead to
physical and psychological impairment, problems with
integration into family and social life, and quality of life.
Problems with endocrine function, musculoskeleton, respi-
ratory tract, liver, kidney, central nervous system, eye, skin,
and mucosa are all common. Some late side effects can start
as early as 3 months after transplantation, whereas othersbecome apparent years or even decades later, with the risk
and type of complication depending on conditioning
regimen before allo-HCT, patient age at the time of trans-
plantation, the presence of comorbidities, and the time be-
tween treatment and follow-up [9]. Thus, GVHD and
conditioning regimens, particularly when full-dose, mye-
loablative, total body irradiation (TBI) is included, play a key
role in the development of late complications [7,8]. TBI
causes damage to tissues with a low potential for repair and
has been implicated in the onset of diverse late complica-
tions after allo-HCT such as cataract formation [10,11],
azoospermia [12], and diabetes [13]. Other etiologic factors
are also in play, including exposure to cytotoxic chemo-
therapy, chronic GVHD and corticosteroid use, and the im-
pacts steroids have on immune deﬁciency and later infection
[7]. Lifestyle factors and physiologic aging are also potentially
involved in the development of complications.
Chronic Kidney Disease
Chronic kidney disease (CKD), a common late complication
of myeloablative allo-HCT, was shown in 1 study to affect 23%
of patients, with a cumulative incidence rate of 27% at 10 years
[14]. Pretransplant risk factors were lower glomerular ﬁltra-
tion rate, female gender, and older age, whereas the occur-
rence of hypertension after transplantation was also a risk
factor. Another study of 1190 adults who underwent mye-
loablative HCT and survived at least 1 year reported a cumu-
lative incidence of CKD of 4.4% at 5 years, including 4.5% of
patients with a matched sibling donor and 10.0% of patients
with an unrelated donor [15]. Older age at HCT, exposure to
cyclosporine, and a primary diagnosis of multiple myeloma
were associated with an increased risk of delayed CKD.
One study evaluating the risk of CKD in allo-HCT re-
cipients found no difference in patients who received
reduced-intensity conditioning (RIC) and those who received
myeloablative conditioning [16]. However, another study
evaluating renal function in children after autologous HCT
reported that of the patients who developed chronic renal
impairment post-transplant, all received TBI and also more
nephrotoxic antibiotics than patients who received chemo-
therapy alone as conditioning [17]. The authors of this study
concluded that TBI was the principal cause of deteriorating
renal function, possibly as a consequence of TBI limiting
compensatory hyperperfusion and resulting in a fall in the
glomerular ﬁltration rate.
Finally, a study of 1635 patients transplanted at a single
center between 1991 and 2002 who survived to day þ131
after HCT found that 376 patients (23%) developed CKD at a
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CKD was associated with grade II acute GVHD (hazard ratio
[HR], 2.0) and grades III to IV acute GVHD (HR, 3.1) and
chronic GVHD (HR, 1.8). However, TBI was not associated
with an increased risk of CKD in this study.
Cardiac and Cardiovascular Complications
In comparison with other post-transplant complications,
cardiac and cardiovascular complications occur at a lower
frequency [19]. Early cardiac and cardiovascular complica-
tions are typically associated with prior patient history,
primary diagnosis, age, associated comorbidities, and the
type of transplantation and conditioning regimen used. Late
cardiac and cardiovascular complications are related to
cytotoxic chemotherapy, mediastinal radiation therapy,
gender, age at transplantation, cardiovascular risk factors,
and GVHD. As with other late complications, late cardiac and
cardiovascular events can occur up to several decades after
allo-HCT [19]. Among 265 patients undergoing allo-HCT
between 1980 and 2000 who survived for at least 2 years,
18 patients (6.8%) experienced an arterial event compared
with 3 patients (2.1%) from a cohort of 145 patients treated
with autologous HCT [20]. Fifteen years after allo-HCT, the
cumulative incidence of an arterial event was 7.5% compared
with 2.3% after autologous HCT. The cumulative incidence of
a ﬁrst arterial event after allo-HCT was 22.1% at 25 years. In
multivariate analysis, allo-HCT together with at least 2 of 4
cardiovascular risk factors (hypertension, dyslipidemia,
diabetes, obesity) were predictive of an arterial event [20].
Given that the median patient age at last follow-up was
39 years, these ﬁndings indicate that long-term survivors
after allo-HCT are at high risk of premature arterial vascular
disease.
Malignant Complications
In addition to these nonmalignant late complications,
patients who undergo HCT are at increased risk of post-
transplant lymphoproliferative disorders, late relapse of the
primary disease, donor-type secondary leukemia or other
malignancies, and solid tumors after allo-HCT. The risk of a
new malignant condition was assessed in 1036 consecutive
patients from 45 transplant centers of the European Coop-
erative Group for Blood and Marrow Transplantation [21].
Transplantation was done before 1986, and patients had
survived more than 5 years. After a median follow-up of
10.7 years, malignant neoplasms were diagnosed in 53
patients, with an actuarial incidence of 3.5% at 10 years and
12.8% at 15 years. Older patient age and treatment of chronic
GVHD with cyclosporine were signiﬁcant risk factors. An
update of this study showed the incidence of secondary
malignancies continued to increase with longer follow-up
time compared with an age-matched control population
[22]. Transplant recipients have also been reported to have
an increased risk of solid cancers, with 1multicenter study of
more than 28,000 allo-HCT recipients reporting that patients
developed new solid tumors at twice the expected rate based
on observed rates in the general population [23]. This risk
was 3-fold higher among patients followed for 15 years
or more.
Both conditioning radiation and chronic GVHD have been
implicated in the development of solid cancers after allo-HCT
transplantation. One study showed the risk of developing a
nonsquamous cell carcinoma after conditioning radiation
was highly dependent on age at exposure, with the risk
9-fold higher in irradiated patients under the age of 30 yearscompared with nonirradiated patients [23]. In contrast, male
gender and chronic GVHD were the main determinants of
risk of squamous cell carcinoma. Another study investigating
the incidence and risk factors for solid tumors after allo-HCT
among 1742 recipients with acute myeloid leukemia who
received high-dose busulfanecyclophosphamide condition-
ing without TBI reported a cumulative incidence of solid
cancers at 5 and 10 years post-HCT of .6% and 1.2%, respec-
tively [24]. Among 2576 patients with chronic myeloid
leukemia, the cumulative incidence at 5 and 10 years was .9%
and 2.4%, respectively. Compared with the general popula-
tion, allo-HCT recipients had a 1.4-fold higher than expected
rate of invasive solid cancers. Again, chronic GVHD was an
independent risk factor, especially for cancers of the oral
cavity. Finally, a multicenter study of 3337 female 5-year
survivors who underwent allo-HCT reported that 52 survi-
vors developed breast cancer at a median of 12.5 years after
HCT [25]. Overall, the 25-year cumulative incidence of breast
cancer was 11%. However, this reached 17% among survivors
who received TBI compared with 3% of those who did not
receive TBI.
Finally, a multicenter study evaluated risk of second solid
cancer after nonmyeloablative or RIC allo-HCT among 2833
patients with acute leukemia or myelodysplastic syndrome
and 1436 patients with lymphoma [26]. There was no
increase in overall cancer risk compared with the general
population (standardized incidence ratio .99, P ¼ 1.00 for
leukemia/myelodysplastic syndrome; standardized inci-
dence ratio .92, P¼ .75 for lymphoma), although therewas an
increased risk of cancer at some sites and the cumulative
incidence at 10 years was 3.35%. Among patients ages 40 to
60 years, if there was no difference in cancer risks between
nonmyeloablative/RIC and myeloablative conditioning in
leukemia/myelodysplastic syndrome patients (HR, .98;
P ¼ .905), in lymphoma patients cancer risks was signiﬁ-
cantly lower after nonmyeloablative/RIC (HR, .51; P ¼ .047).
Immune Deﬁciency
Regarding immune reconstitution after allo-HCT, GVHD,
with an incidence of 40% to 70% [9], has detrimental effects
on the thymus, leading to decreased generation of naive T
cells. GVHD also has direct impacts on T cellemediated im-
munity, which in turn affects B cell function with down-
stream consequences of secretory IgA and IgG deﬁciency.
Moreover, steroid treatment of GVHD further exacerbates
immune dysfunction [7].
REDUCING THE RISKS OF COMPLICATIONS: TOWARD
CONDITIONING REGIMENS INDIVIDUALIZED
To ameliorate the risks associated with myeloablative
regimens, nonmyeloablative and RIC regimens are increas-
ingly used in the allo-HCT setting. It is well established that
RIC can reduce short-term acute toxicity, but regarding
chronic GVHD results are less clear. Indeed, chronic GVHD
incidence is not decreased in RIC [6], because RIC regimens
are largely used in older patients and those with more
advanced disease with peripheral blood stem cells as the
main graft source, all well-established risk factors for chronic
GVHD.
The choice between RIC and myeloablative conditioning
remains a matter of debate. Despite the only prospective
study comparing RIC and myeloablative conditioning
regimens has been closed for lower survival in the reduced-
intensity arm, it is difﬁcult to draw ﬁnal conclusion because
the study has not been published so far and the
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comorbidities at transplant) are unknown. Indeed, it is well
established that the decrease toxicity of RIC regimen occurs
at the cost of an increase in relapse incidence. RIC regimens
have been developed for elderly patients, heavily pretreated
patients, and patients with comorbidities [27,28], precluding
the use of myeloablative conditioning regimens. In patients
with good medical condition, eligible for myeloablative
conditioning, high-dose TBI, a major risk factor of long-term
complications as highlighted above, might be probably
abandoned in favor of i.v. busulfan because results between
cyclophosphamide plus i.v. busulfan or TBI in patients with
acute myeloid leukemia were comparable in the European
Group for Blood And Marrow Transplantation study [29] and
even better with i.v. busulfan in the Center for International
Blood and Marrow Transplant Research study [30]. Further-
more, the development of a reduced-toxicity conditioning
regimen, such as the ﬂudarabine plus myeloablative doses of
9.6 to 12.8 mg/kg i.v. busulfan, appears to be an attractive
alternative to the classic high-dose therapy.
Overall, it is likely that as allo-HCT continues to evolve,
individualized reduced-toxicity conditioning, RIC, and non-
myeloablative conditioning regimens will be increasingly
used in place of myeloablative regimens or in patients pre-
viously not eligible for allo-HCT. Practical guidelines are
needed to address important clinical questions, such as the
optimal stem cell source for allo-HCT, selection and dose of
chemotherapeutic regimen for conditioning, and the role of
pharmacogenetics and pharmacokinetics in personalized
transplantation [31-33]. In adult HLA-matched sibling
transplants, current evidence suggests that peripheral blood
stem cell transplantation has a lower risk of relapse and
better disease-free survival compared with bone marrow
transplantation but at the expense of a higher risk of both
severe acute and chronic GVHD [31]. In the unrelated donor
setting, limited evidence suggests similar overall and
disease-free survival for peripheral blood and bone marrow
transplantation, but with a higher risk of chronic GVHD for
the former. However, the risks and beneﬁts of each strategy
likely change with different conditioning regimens, prophy-
laxis strategies, and treatment of GVHD. As experience with
individual chemotherapeutic agents continues to grow,
knowledge of their pharmacodynamics, pharmacokinetics,
and pharmacogenetics will play a greater role in tailoring
drug selection to patients [33]. Finally, improved counseling
along with screening and preventive practices for long-term
survivors after allo-HCT will play an important role in
reducing the risk of late complications [34].
CONCLUSIONS
Although allo-HCT survivors generally enjoy good long-
term health, for many others long-term survivorship is not
accompanied by full restoration of health and instead is
associated with a substantial burden of chronic morbidities.
These long-term side effects have a multifactorial and com-
plex etiology but in many cases are associated with the use of
high-dose TBI, myeloablative conditioning regimens, and the
onset of chronic GVHD. The fact that these long-term com-
plications have been brought into focus is a reﬂection that
short-term survivability has improved with the considerable
changes in allo-HCT techniques over the past several
decades. The natural history of these late effects will likely
also change in the future with the introduction of improved
conditioning regimens. However, lifelong monitoring con-
trols, patient counseling, and preventative treatmentmeasures are mandatory and require a close partnership
between the transplant center, organ-speciﬁc specialties,
and local primary care providers. The patient can also play a
major role through engagement in health maintenance be-
haviors. Given there is considerable distance between the
goal of universal cure for transplantation recipients and the
current burden of long-term morbidity, it is imperative that
clinicians are prepared to deal with the consequences of our
therapeutic success.ACKNOWLEDGMENTS
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